Teva Pharma (TEVA) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY23 Guidance

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $0.60, in-line with the analyst estimate of $0.60. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.72 billion.

GUIDANCE:

Teva Pharma sees FY2023 EPS of $2.25-$2.55, versus the consensus of $2.28. Teva Pharma sees FY2023 revenue of $15.1-15.5 billion, versus the consensus of $15.14 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Teva Pharma (TEVA) PT Raised to $48 at UBS
• Barclays Downgrades Ipsen SA (IPN:FP) (IPSEF) to Underweight
• Prabhudas Lilladher Upgrades GE Vernova T&D India (GVTD:IN) to Buy (1)